DLL3 and small cell lung carcinoma: Within non‐NE SCLC cells, 75% expresses POU2F3.[59] Additionally, ≈17% of SCLC patients with low DLL3 expression exhibit high ASCL1 expression.[60] By incorporating EV transcription factors for SCLC subtypes into the DLL3‐based biomarker classifier, our ILN biochip assay can detect more than 90% of LS‐ and ES‐SCLC patients and accurately determine their subtypes.